William Blair Weighs in on Collegium Pharmaceutical, Inc.’s Q3 2021 Earnings (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Research analysts at William Blair lowered their Q3 2021 earnings per share (EPS) estimates for Collegium Pharmaceutical in a note issued to investors on Thursday, April 15th. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings per share of $0.53 for the quarter, down from their prior forecast of $0.54. William Blair also issued estimates for Collegium Pharmaceutical’s Q4 2021 earnings at $0.52 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 25th. The specialty pharmaceutical company reported $0.20 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.09). Collegium Pharmaceutical had a return on equity of 12.64% and a net margin of 5.71%. The company had revenue of $76.27 million for the quarter, compared to analyst estimates of $76.77 million.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, March 4th. HC Wainwright raised their price objective on shares of Collegium Pharmaceutical from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, January 11th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Collegium Pharmaceutical in a report on Tuesday, December 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $23.50.

Shares of NASDAQ:COLL opened at $23.46 on Friday. The company’s fifty day moving average price is $23.91 and its 200 day moving average price is $21.69. Collegium Pharmaceutical has a 12 month low of $15.66 and a 12 month high of $26.91. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.08 and a quick ratio of 1.01. The firm has a market capitalization of $825.89 million, a P/E ratio of 47.88, a P/E/G ratio of 0.73 and a beta of 1.27.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 50,075 shares of the business’s stock in a transaction that occurred on Monday, March 15th. The shares were sold at an average price of $25.30, for a total transaction of $1,266,897.50. Following the completion of the sale, the director now directly owns 7,078 shares in the company, valued at $179,073.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Joseph Ciaffoni sold 64,768 shares of the business’s stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $22.67, for a total transaction of $1,468,290.56. Following the sale, the chief executive officer now owns 343,075 shares of the company’s stock, valued at $7,777,510.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 130,259 shares of company stock valued at $3,100,737. 8.08% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC grew its stake in Collegium Pharmaceutical by 2.3% during the third quarter. Cubist Systematic Strategies LLC now owns 32,594 shares of the specialty pharmaceutical company’s stock worth $679,000 after buying an additional 742 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Collegium Pharmaceutical by 0.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 227,139 shares of the specialty pharmaceutical company’s stock worth $4,550,000 after buying an additional 898 shares during the period. The Manufacturers Life Insurance Company grew its stake in Collegium Pharmaceutical by 4.5% during the fourth quarter. The Manufacturers Life Insurance Company now owns 21,002 shares of the specialty pharmaceutical company’s stock worth $421,000 after buying an additional 900 shares during the period. Renaissance Group LLC grew its stake in Collegium Pharmaceutical by 2.6% during the fourth quarter. Renaissance Group LLC now owns 37,226 shares of the specialty pharmaceutical company’s stock worth $746,000 after buying an additional 940 shares during the period. Finally, Great West Life Assurance Co. Can grew its stake in Collegium Pharmaceutical by 58.9% during the third quarter. Great West Life Assurance Co. Can now owns 3,614 shares of the specialty pharmaceutical company’s stock worth $99,000 after buying an additional 1,340 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting.

Featured Story: Trading Ex-Dividend Strategy

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit